PT-141 (Bremelanotide): What It Is and What the Research Shows

PT-141, also known as bremelanotide, is a synthetic peptide analogue of α-melanocyte-stimulating hormone (α-MSH) acting on the melanocortin receptor system. Unlike erectile dysfunction medicines that work mainly on blood flow, PT-141 is interesting for its action on the central nervous system and the melanocortin receptors tied to sexual desire and sexual behaviour. Bremelanotide has been studied both in men with erectile dysfunction and in women with reduced sexual desire; the strongest clinical base to date is in premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD).

What is PT-141?

PT-141 is a synthetic analogue of α-MSH belonging to the melanocortin receptor agonists. Studies show bremelanotide has affinity for several melanocortin receptors, with MC3R and MC4R mattering most for its sexual effects. These receptors are expressed in various regions of the central nervous system, including structures involved in regulating sexual behaviour. This makes its mechanism different from PDE5 inhibitors such as sildenafil, which act mainly through the NO–cGMP pathway and increased blood flow.

How does PT-141 act?

The melanocortin system participates in a range of physiological processes: appetite and energy balance, pigmentation, stress responses, sexual behaviour and sexual motivation. PT-141 activates melanocortin receptors in the central nervous system and can thereby influence the neural mechanisms tied to sexual desire and arousal. Preclinical work showed that activating this system can elicit sexual responses in animal models; in humans, subsequent clinical studies demonstrated physiological and subjective effects on sexual function.

PT-141 and sexual desire

A defining feature of bremelanotide is that its potential effect is not limited to the physiological component of sexual function. Sexual desire involves complex interactions between brain structures, neurotransmitters, hormonal factors, psychological factors and sexual stimuli — and the melanocortin system is part of that network. This is one reason PT-141 has been studied in hypoactive sexual desire disorder (HSDD), a condition of persistently reduced sexual desire causing significant personal or interpersonal distress.

What do the studies in men show?

Early clinical research pointed to a potential effect on erectile function. A randomised, double-blind 2004 study examined healthy men and men with mild-to-moderate erectile dysfunction. After intranasal administration of PT-141, a dose-dependent erectile response was observed. At doses above 7 mg the effect was statistically distinguishable from placebo, with the first erection occurring roughly 30 minutes after administration and a mean elimination half-life of about 1.85–2.09 hours. The most commonly reported adverse reactions were flushing and nausea.

PT-141 in men who do not respond to sildenafil

In a randomised study of 342 men with erectile dysfunction unresponsive to sildenafil, bremelanotide produced a higher rate of positive clinical outcomes than placebo — 33.5% versus 8.5%. The authors stressed the need for further work to optimise dosing and administration. Interesting results, but they do not make PT-141 a universal solution for erectile dysfunction.

PT-141 in women

Bremelanotide's most significant clinical programme concerns HSDD in premenopausal women. Two large Phase 3 trials, known as RECONNECT, enrolled 1,267 women randomised to bremelanotide or placebo for 24 weeks. The results showed statistically significant increases in sexual desire and reductions in the distress associated with low desire. In the integrated analysis, the desire score improved by roughly 0.35 points more than placebo, while desire-related distress fell by roughly 0.33 points more than placebo. This is one of the most substantial clinical bases for a melanocortin agonist in female sexual dysfunction.

How durable is the effect?

After the core 24-week phase, a subset of participants continued into a 52-week open-label extension. Of 856 eligible women, 684 chose to participate and 272 completed the full period. No new significant safety signals were identified. The most common treatment-related adverse reactions were nausea (40.4%), flushing (20.6%) and headache (12.0%). The authors reported that improvements in desire and related distress were maintained.

What is HSDD?

Hypoactive Sexual Desire Disorder does not simply mean “low libido”. The medical concept involves persistently reduced or absent sexual desire causing significant personal distress or relationship problems. Sexual desire can be influenced by psychological factors, stress, relationships, medications, hormonal changes, other conditions and neurotransmitter mechanisms. Bremelanotide's action should therefore not be read as simply “switching on” libido.

PT-141 versus PDE5 inhibitors

PDE5 inhibitors such as sildenafil and tadalafil mainly amplify the NO → cGMP → smooth muscle relaxation → increased blood flow pathway — that is, the physiological mechanism of erection. With bremelanotide the interest lies in the chain melanocortin receptors → central nervous system → sexual motivation, arousal and physiological sexual response. This is why melanocortin agonists represent a distinct pharmacological strategy in sexual dysfunction.

Side effects

Clinical studies show bremelanotide has comparatively well-characterised adverse reactions — most often nausea, flushing and headache, all significantly more frequent than placebo in the Phase 3 trials. This is an important part of the molecule's profile, and a reminder that a “stronger effect” should not automatically be read as a “better effect”.

What do we know about safety?

Unlike many experimental peptides, bremelanotide has a substantially larger base of human clinical data — the Phase 3 programme enrolled over 1,200 women, and the 52-week extension adds information on prolonged exposure. Even so, the results belong to a specific approved formulation, population and indication. Data on medical bremelanotide does not automatically mean every product sold as “PT-141” shares the same purity, stability, pharmacokinetics or safety profile.

Limits of the evidence

First, the strongest modern data concerns one indication — HSDD in a defined group of women. Second, the results in men are more limited and historically used different routes of administration. Third, sexual desire is hard to measure objectively; trial endpoints rely on validated questionnaires and self-report. Notably, a later analysis questioned the validity of some of the endpoints used and judged the overall effect size to be modest — worth bearing in mind when interpreting the Phase 3 results.

PT-141 at a glance

• Name — PT-141 / bremelanotide;
• Class — melanocortin receptor agonist;
• Key receptors — MC3R / MC4R;
• Sexual function — studied in men and women;
• HSDD — Phase 3 clinical data;
• Erectile dysfunction — clinically studied, more limited data;
• Most common adverse reactions — nausea, flushing, headache;
• Human clinical base — substantially larger than most experimental peptides;
• Status — bremelanotide has a medical use for a specific indication; that does not make every product labelled PT-141 equivalent to the approved medicine.

Conclusion

PT-141, or bremelanotide, is an interesting example of a peptide that moved from experimental molecule to clinically developed melanocortin agonist. Unlike many peptides, it has randomised human trials, including a large Phase 3 programme in women with HSDD. In men, early studies showed potential for stimulating erection, including in some patients unresponsive to sildenafil, though that data is more limited. Its key scientific distinction is the mechanism — rather than mainly increasing local blood flow, it engages the melanocortin system tied to central regulation of sexual behaviour. At the same time, the clinical effects are not large, and the adverse reactions are well documented. PT-141 should be seen not as a “super-libido peptide” but as a molecule with a genuinely studied, yet specific, pharmacological effect on sexual function.

1. 1.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019.
2. 2.Simon JA, Kingsberg SA, Portman D, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019.
3. 3.Diamond LE, Earle DC, Rosen RC, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004.
4. 4.Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol. 2008.
5. 5.Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016.
6. 6.Pfaus JG, Sadiq A, Spana C, et al. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022.
7. 7.Molinoff PB, Shadiack AM, Earle D, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003.
8. 8.Ückert S, Bannowsky A, Albrecht K, et al. Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions. Expert Opin Investig Drugs. 2014.
9. 9.Spielmans GI, Ellefson EM. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. J Sex Res. 2024.